Akanda (AKAN) Competitors $1.34 -0.02 (-1.47%) Closing price 04:00 PM EasternExtended Trading$1.35 +0.01 (+1.04%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKAN vs. KPRX, MTNB, APM, MBIO, EVOK, ALZN, BCLI, ACXP, INAB, and ARTLShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Kiora Pharmaceuticals (KPRX), Matinas Biopharma (MTNB), Aptorum Group (APM), Mustang Bio (MBIO), Evoke Pharma (EVOK), Alzamend Neuro (ALZN), Brainstorm Cell Therapeutics (BCLI), Acurx Pharmaceuticals (ACXP), IN8bio (INAB), and Artelo Biosciences (ARTL). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Its Competitors Kiora Pharmaceuticals Matinas Biopharma Aptorum Group Mustang Bio Evoke Pharma Alzamend Neuro Brainstorm Cell Therapeutics Acurx Pharmaceuticals IN8bio Artelo Biosciences Kiora Pharmaceuticals (NASDAQ:KPRX) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations. Do institutionals & insiders believe in KPRX or AKAN? 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 20.4% of Akanda shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor KPRX or AKAN? In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Akanda. MarketBeat recorded 3 mentions for Kiora Pharmaceuticals and 2 mentions for Akanda. Kiora Pharmaceuticals' average media sentiment score of 0.96 beat Akanda's score of 0.43 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Kiora Pharmaceuticals Positive Akanda Neutral Do analysts recommend KPRX or AKAN? Kiora Pharmaceuticals presently has a consensus target price of $10.00, indicating a potential upside of 247.22%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Kiora Pharmaceuticals is more favorable than Akanda.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Akanda 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is KPRX or AKAN more profitable? Akanda's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A -47.17% -34.00% Akanda N/A N/A N/A Which has better valuation & earnings, KPRX or AKAN? Kiora Pharmaceuticals has higher revenue and earnings than Akanda. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora Pharmaceuticals$16.02M0.62$3.60M-$2.91-0.99Akanda$840K2.28-$4.10MN/AN/A Which has more risk and volatility, KPRX or AKAN? Kiora Pharmaceuticals has a beta of -0.64, suggesting that its stock price is 164% less volatile than the S&P 500. Comparatively, Akanda has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. SummaryKiora Pharmaceuticals beats Akanda on 8 of the 13 factors compared between the two stocks. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.92M$10.48B$5.70B$9.79BDividend YieldN/A1.90%3.77%4.10%P/E RatioN/A20.6730.8625.27Price / Sales2.2831.09403.8888.61Price / CashN/A24.9525.2228.45Price / Book0.453.459.516.00Net Income-$4.10M$209.94M$3.26B$265.34M7 Day Performance-2.19%3.96%4.50%2.79%1 Month Performance10.74%12.75%5.22%1.51%1 Year Performance-51.09%-9.39%31.92%25.40% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkanda1.1264 of 5 stars$1.34-1.5%N/A-50.4%$1.92M$840K0.00110Positive NewsShort Interest ↑KPRXKiora Pharmaceuticals3.6122 of 5 stars$2.50+2.0%$10.00+300.0%-22.1%$7.60M$16.02M-0.8610Short Interest ↓Gap UpMTNBMatinas Biopharma1.5265 of 5 stars$1.48-7.5%N/AN/A$7.53MN/A-0.3130Short Interest ↓Gap UpAPMAptorum Group0.6851 of 5 stars$1.40-1.1%N/A-56.6%$7.51M$430K0.0030Positive NewsMBIOMustang Bio1.2333 of 5 stars$1.70-3.4%N/A-90.4%$7.45MN/A-0.02100Positive NewsShort Interest ↓Gap DownEVOKEvoke Pharma0.541 of 5 stars$4.99-8.8%N/A-11.0%$7.44M$10.25M-1.744Earnings ReportShort Interest ↓Gap DownALZNAlzamend Neuro2.7593 of 5 stars$2.44+1.7%$180.00+7,277.0%-87.0%$7.08MN/A0.004Short Interest ↑BCLIBrainstorm Cell Therapeutics2.4858 of 5 stars$0.63+5.2%N/A-87.8%$6.98MN/A-0.1940Short Interest ↓Gap UpACXPAcurx Pharmaceuticals3.0221 of 5 stars$4.44-0.9%$31.00+598.2%-87.3%$6.84MN/A-0.323Earnings ReportAnalyst UpgradeGap UpINABIN8bio3.9112 of 5 stars$2.25-0.9%$180.00+7,900.0%-88.7%$6.82MN/A-0.2520News CoverageShort Interest ↓ARTLArtelo Biosciences2.8736 of 5 stars$9.72-3.1%$24.00+146.9%+28.6%$6.80MN/A-0.545Earnings ReportAnalyst ForecastShort Interest ↓ Related Companies and Tools Related Companies KPRX Competitors MTNB Competitors APM Competitors MBIO Competitors EVOK Competitors ALZN Competitors BCLI Competitors ACXP Competitors INAB Competitors ARTL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKAN) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access